Osimertinib - Wikipedia
ウェブOsimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Osimertinib or Platinum–Pemetrexed in EGFR T790M ...
ウェブ2017年2月16日 · Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with...
Osimertinib Resistance: Molecular Mechanisms and ...
ウェブ2023年1月30日 · Timeline of development and approvals of osimertinib. Abbreviations: EGFR: epidermal growth factor receptor, TKI: tyrosine kinase inhibitor, FDA: Food and Drug Administration, NSCLC: non-small-cell lung cancer. Figure of osimertinib molecule: National Center for Biotechnology Information (2023).
A consensus on the role of osimertinib in non-small cell lung ...
ウェブ2018年5月28日 · Osimertinib (AZD9291 or Tagrisso) is a structurally mono-anilino-pyrimidine compound, orally available, third-generation EGFR-TKI that irreversibly binds to the EGFR kinase by targeting the cysteine residue at codon 797 (C797).
Identification of Novel Pathways of Osimertinib Disposition ...
ウェブ2018年4月30日 · Wild-type and h2D6 animals were administered osimertinib (25 mg/kg p.o.) and blood samples collected at the indicated timepoints for measurement of (C) osimertinib and (D) OH-2-osimertinib. Data shown are mean ± SD with n …
Osimertinib successfully combats EGFR-negative ...
ウェブ2020年5月12日 · In GBM patient-derived xenografts mice, oral administration of osimertinib (40 mg· kg −1 ·d −1, for 18 days) significantly suppressed the tumor growth (TGI = 74.5%) and inhibited eIF4E...
Osimertinib with Chemotherapy in EGFR -Mutated NSCLC
ウェブ2024年1月31日 · Abstract. To the Editor: In the report by Planchard et al. (Nov. 23 issue) 1 on the FLAURA2 trial of osimertinib with or without chemotherapy in EGFR -mutated advanced non–small-cell lung cancer...
Osimertinib as first-line treatment for advanced epidermal ...
ウェブ2021年12月1日 · Osimertinib is used in the second-line treatment because of the resistance imparted by T790M, and therefore, the optimal first-line treatment for patients with L858R remains debatable. A phase II trial assessing the effect of osimertinib in patients with uncommon mutations reported a median PFS of 8.2 months [ 27 ].
Distinct Progression and Efficacy of First-Line Osimertinib ...
ウェブ2024年1月17日 · PFS and OS were estimated using the Kaplan–Meier method, and comparisons were performed with the log-rank test. PFS was defined as the duration from the date of administration of the first dose of OSI to disease progression
ウェブosimertinib administration at any dose, the progression-free survival (PFS) for patients receiving 40 mg of osimertinib every other day, and relative dose intensity (RDI) of the whole duration of administering osimertinib were PFS was
- 一部の検索結果が削除されました
コンテンツに移動